Atorvastatin Reduces the Ability of Clopidogrel to Inhibit Platelet Aggregation
University of North Carolina at Chapel Hill · Ann Arbor VA Medical Center · +1 more institution
Abstract
BACKGROUND: We observed that the prodrug clopidogrel was less effective in inhibiting platelet aggregation with coadministration of atorvastatin during point-of-care platelet function testing. Because atorvastatin is metabolized by cytochrome P450 (CYP) 3A4, we hypothesized that clopidogrel might be activated by CYP3A4. METHODS AND RESULTS: Platelet aggregation was measured in 44 patients undergoing coronary artery stent implantation treated with clopidogrel or clopidogrel plus pravastatin or atorvastatin, and in 27 volunteers treated with clopidogrel and either erythromycin or troleandomycin, CYP3A4 inhibitors, or rifampin, a CYP3A4 inducer. Atorvastatin, but not pravastatin, attenuated the antiplatelet…
Citation impact
- FWCI
- 44.93
- Percentile
- 100%
- References
- 37
Authors
10- WCWei C. LauCorresponding
University of North Carolina at Chapel Hill, Ann Arbor VA Medical Center, Indiana University South Bend
- LWLucy Waskell
University of North Carolina at Chapel Hill, Ann Arbor VA Medical Center, Indiana University South Bend
- PBPaul B. Watkins
University of North Carolina at Chapel Hill, Ann Arbor VA Medical Center, Indiana University South Bend
- CJCharlene J. Neer
University of North Carolina at Chapel Hill, Ann Arbor VA Medical Center, Indiana University South Bend
- KHKevin Horowitz
University of North Carolina at Chapel Hill, Ann Arbor VA Medical Center, Indiana University South Bend
Topics & keywords
- Clopidogrel
- Atorvastatin
- Medicine
- Pharmacology
- Platelet
- Pravastatin
- CYP3A4
- Aspirin
- Good health and well-being